DARPP-32 Inhibitors
DARPP-32 inhibitors constitute a diverse class of chemical compounds designed to modulate the activity of DARPP-32, a critical regulator of neurotransmitter signaling in the brain. While direct DARPP-32 inhibitors are limited, various chemicals offer insights into the intricate regulatory pathways governing DARPP-32 expression and function. Dihydrexidine and SKF 81297, both dopamine D1 receptor agonists, indirectly modulate DARPP-32 through the cAMP/PKA pathway. By activating D1 receptors, they elevate cAMP levels, leading to PKA activation and subsequent phosphorylation and inhibition of DARPP-32. In contrast, SCH 23390, a dopamine D1 receptor antagonist, inhibits DARPP-32 indirectly by blocking D1 receptors, reducing cAMP/PKA pathway activation. Tandospirone, a serotonin 5-HT1A receptor agonist, indirectly influences DARPP-32 activity through increased serotonin signaling, activating the cAMP/PKA pathway. Haloperidol, an antipsychotic, indirectly modulates DARPP-32 by blocking dopamine D2 receptors, reducing cAMP/PKA pathway activation.
Compounds like SCH 39166, Butaclamol, and Sumanirole target specific dopamine receptor subtypes, offering nuanced insights into the differential modulation of DARPP-32 by dopamine receptor signaling. PNU-101387, a dopamine D3 receptor antagonist, and 7-OH-DPAT, a D3 receptor agonist, further explore the specific impact of D3 receptor activation on DARPP-32 function. Clozapine, an atypical antipsychotic, and Fenoldopam, a selective D1 receptor agonist, provide additional perspectives on DARPP-32 modulation, reflecting the complex interplay between neurotransmitter signaling and intracellular pathways. In conclusion, DARPP-32 inhibitors, while predominantly indirect, offer a comprehensive approach to unraveling the intricate regulatory mechanisms governing DARPP-32 activity. The indirect modulation through neurotransmitter receptors provides valuable tools for researchers investigating the dynamic interplay between neurotransmitter signaling and intracellular pathways involving DARPP-32.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $179.00 $733.00 | 2 | |
SCH 23390 is a selective dopamine D1 receptor antagonist. By blocking D1 receptors, it indirectly influences DARPP-32 activity. D1 receptor inhibition reduces cAMP/PKA pathway activation, leading to decreased phosphorylation and inhibition of DARPP-32. | ||||||
Tandospirone hydrochloride | 99095-10-0 | sc-204320 sc-204320A | 10 mg 50 mg | $132.00 $559.00 | ||
Tandospirone is a serotonin 5-HT1A receptor agonist. Through 5-HT1A receptor activation, it indirectly modulates DARPP-32 activity. Increased serotonin signaling influences cAMP/PKA pathway activation, leading to phosphorylation and inhibition of DARPP-32. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol is a classic antipsychotic that indirectly modulates DARPP-32 through dopamine D2 receptor antagonism. D2 receptor blockade reduces cAMP/PKA pathway activation, leading to decreased phosphorylation and inhibition of DARPP-32. | ||||||
SCH 39166 hydrobromide | 1227675-51-5 | sc-204270 sc-204270A | 10 mg 50 mg | $234.00 $941.00 | ||
SCH 39166 is a selective dopamine D1 receptor antagonist. Through D1 receptor inhibition, it indirectly modulates DARPP-32 activity via the cAMP/PKA pathway. Reduced D1 receptor signaling decreases cAMP/PKA pathway activation, leading to decreased phosphorylation and inhibition of DARPP-32. | ||||||
(+)-Butaclamol hydrochloride | 55528-07-9 | sc-252525 | 5 mg | $132.00 | ||
Butaclamol is a dopamine D2 receptor antagonist. Through D2 receptor blockade, it indirectly influences DARPP-32 activity. Reduced D2 receptor signaling decreases cAMP/PKA pathway activation, leading to decreased phosphorylation and inhibition of DARPP-32. | ||||||
Sonepiprazole | 170858-33-0 | sc-364623 sc-364623A | 5 mg 25 mg | $95.00 $384.00 | ||
PNU-101387 is a selective dopamine D3 receptor antagonist. Through D3 receptor blockade, it indirectly influences DARPP-32 activity. Reduced D3 receptor signaling decreases cAMP/PKA pathway activation, leading to decreased phosphorylation and inhibition of DARPP-32. | ||||||
7-Hydroxy-DPAT·HBr | 76135-30-3 | sc-200400 sc-200400A | 10 mg 50 mg | $104.00 $250.00 | 5 | |
7-OH-DPAT is a dopamine D3 receptor agonist. By activating D3 receptors, it indirectly modulates DARPP-32 through the cAMP/PKA pathway. Increased D3 receptor signaling leads to elevated cAMP levels, activating PKA and resulting in phosphorylation and inhibition of DARPP-32. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine is an atypical antipsychotic that indirectly modulates DARPP-32 through dopamine receptor antagonism. By blocking multiple dopamine receptor subtypes, including D1 and D2 receptors, it decreases cAMP/PKA pathway activation, leading to decreased phosphorylation and inhibition of DARPP-32. | ||||||
Fenoldopam hydrochloride | 67227-56-9 | sc-279160 | 10 mg | $159.00 | ||
Fenoldopam is a selective dopamine D1 receptor agonist. By activating D1 receptors, it indirectly influences DARPP-32 through the cAMP/PKA pathway. Increased D1 receptor signaling leads to elevated cAMP levels, activating PKA and resulting in phosphorylation and inhibition of DARPP-32. | ||||||